This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
FULGENT GENETIC (FLGT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
FULGENT GENETIC (FLGT) closed at $83.53 in the latest trading session, marking a +1.17% move from the prior day.
FULGENT GENETIC (FLGT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, FULGENT GENETIC (FLGT) closed at $75.69, marking a +1.16% move from the previous day.
FULGENT GENETIC (FLGT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, FULGENT GENETIC (FLGT) closed at $84, marking a +0.1% move from the previous day.
FULGENT GENETIC (FLGT) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
FULGENT GENETIC (FLGT) delivered earnings and revenue surprises of 10.02% and 13.35%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
FULGENT GENETIC (FLGT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
FULGENT GENETIC (FLGT) closed the most recent trading day at $73.01, moving +1.61% from the previous trading session.
What's in Store for Fulgent Genetics' (FLGT) Q1 Earnings?
by Zacks Equity Research
COVID-19 testing and NGS-based testing solutions are expected to have contributed to Fulgent Genetics' (FLGT) Q1 earnings.
FULGENT GENETIC (FLGT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
FULGENT GENETIC (FLGT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FULGENT GENETIC (FLGT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
FULGENT GENETIC (FLGT) closed at $87.64 in the latest trading session, marking a +0.52% move from the prior day.
FULGENT GENETIC (FLGT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
FULGENT GENETIC (FLGT) closed at $86.78 in the latest trading session, marking a -0.99% move from the prior day.
FULGENT GENETIC (FLGT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, FULGENT GENETIC (FLGT) closed at $88.95, marking a +1.37% move from the previous day.
FULGENT GENETIC (FLGT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
FULGENT GENETIC (FLGT) closed at $85.24 in the latest trading session, marking a -0.42% move from the prior day.
Logitech, Harley-Davidson, Fulgent Genetics, Bio-Rad Laboratories and IDEXX Laboratories highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Logitech, Harley-Davidson, Fulgent Genetics, Bio-Rad Laboratories and IDEXX Laboratories highlighted as Zacks Bull and Bear of the Day
COVID-19 Resurgence Accelerates Diagnostic Testing: 3 Top Picks
by Urmimala Biswas
We have narrowed down our search to the following stocks, FLGT, BIO and IDXX based on a favorable Zacks Rank and strong prospects for 2021.
Is FULGENT GENETIC (FLGT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (FLGT) Outperforming Other Medical Stocks This Year?
Has FULGENT GENETIC (FLGT) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (FLGT) Outperforming Other Medical Stocks This Year?
Zacks.com featured highlights include: Amkor Tech, Daqo New Energy Corp and Fulgent Genetics
by Zacks Equity Research
Zacks.com featured highlights include: Amkor Tech, Daqo New Energy Corp and Fulgent Genetics
Buy These 3 Stocks With Momentum Anomaly for Higher Returns
by Zacks Equity Research
Amkor Technology (AMKR), Daqo New Energy (DQ) and Fulgent Genetics (FLGT) are currently witnessing a short-term pullback in price. So, make sure you take full advantage of it.
FULGENT GENETIC (FLGT) Moves 8% Higher: Will This Strength Last?
by Zacks Equity Research
FULGENT GENETIC (FLGT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
FULGENT GENETIC (FLGT) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
FULGENT GENETIC (FLGT) delivered earnings and revenue surprises of 40.59% and 30.77%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Fulgent Genetics (FLGT) in Q4 Earnings?
by Zacks Equity Research
We expect strong demand for Fulgent Genetics' (FLGT) end-to-end tests for COVID-19 to have continued through the fourth quarter.
FULGENT GENETIC (FLGT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
FULGENT GENETIC (FLGT) closed at $110.38 in the latest trading session, marking a +1.55% move from the prior day.
Is FULGENT GENETIC (FLGT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (FLGT) Outperforming Other Medical Stocks This Year?
Top Ranked Momentum Stocks to Buy for February 24th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, February 24th
FULGENT GENETIC (FLGT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
FULGENT GENETIC (FLGT) closed at $170.98 in the latest trading session, marking a -0.86% move from the prior day.
Top Ranked Momentum Stocks to Buy for February 9th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, February 9th.